Premas Biotech Secures PRIP Funding for AI-Driven 3D Breast Cancer Organoid Platform
Advertisement
With PRIP support, Premas Biotech will now advance the technology beyond the proof-of-concept stage, generating evidence needed for future clinical validation and broader adoption.
Gurugram-based biotech company Premas Biotech has received Government of India funding under the PRIP scheme to accelerate the development of AXTEX-4D, an AI-driven 3D breast cancer organoid platform designed to help identify the most effective chemotherapy for individual patients before treatment begins using patient-derived tumour models.
Dr Nupur Mehrotra Arora, Co-Founder and Director, Operations at Premas Biotech, said, “Through this project, we aim to move closer to a future where chemotherapy selection for breast cancer can be guided by patient-specific tumour response rather than empirical decision-making alone. Our broader vision is to make functional precision oncology more accessible, affordable and relevant for Indian patients.”
The AXTEX-4D platform combines a three-dimensional tissue culture system with AI-enabled analysis to generate tumour organoids from biopsy-derived cancer cells.
The cells are cultured on a non-woven polymer fibre matrix, allowing them to develop into tissueoids that closely replicate the architecture and biological characteristics of human tumours.
These models preserve important features such as cell-to-cell interactions, oxygen gradients and drug penetration barriers, making them more representative of real tumours than conventional two-dimensional laboratory cultures.
By evaluating the response of these patient-derived organoids to different chemotherapy regimens, researchers aim to identify treatments that are more likely to benefit individual patients while reducing unnecessary exposure to ineffective drugs and associated toxicities.
The approach could also help clinicians make faster, more evidence-based treatment decisions and potentially lower the cost of trial-and-error chemotherapy.
With PRIP support, Premas Biotech will now advance the technology beyond the proof-of-concept stage by developing patient-derived organoids, carrying out molecular and functional characterisation, assessing chemotherapy responses and generating evidence needed for future clinical validation and broader adoption.
Stay tuned for more such updates on Digital Health News
